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Abstract
Inflammation and microglial activation are associated with Alzheimer’s disease (AD) pathology. Somewhat surpris-
ingly, injection of a prototypical inflammatory agent, lipopolysaccharide (LPS) into brains of amyloid precursor pro-
tein (APP) transgenic mice clears some of the pre-existing amyloid deposits. It is less well understood how brain
inflammation modulates tau pathology in the absence of Ab. These studies examined the role of LPS-induced
inflammation on tau pathology. We used transgenic rTg4510 mice, which express the P301L mutation (4R0N
TauP301L) and initiate tau pathology between 3-5 months of age. First, we found an age-dependent increase in
several markers of microglial activation as these rTg4510 mice aged and tau tangles accumulated. LPS injections
into the frontal cortex and hippocampus induced significant activation of CD45 and arginase 1 in rTg4510 and
non-transgenic mice. In addition, activation of YM1 by LPS was exaggerated in transgenic mice relative to non-
transgenic animals. Expression of Ser199/202 and phospho-tau Ser396 was increased in rTg4510 mice that received
LPS compared to vehicle injections. However, the numbers of silver-positive neurons, implying presence of more
pre- and mature tangles, was not significantly affected by LPS administration. These data suggest that inflammatory
stimuli can facilitate tau phosphorylation. Coupled with prior results demonstrating clearance of Ab by similar LPS
injections, these results suggest that brain inflammation may have opposing effects on amyloid and tau pathology,
possibly explaining the failures (to date) of anti-inflammatory therapies in AD patients.
Background
Tauopathies consist of intracellular accumulation of the
microtubule-associated protein tau in the somatodendri-
tic compartment associated with hyperphosphorylation
and aggregation of the protein. Tau dysfunction can
lead to neurodegeneration, motor dysfunction, and
behavioral deficits in animal models that express
mutated forms of the protein [1-4]. One of the most
common tauopathies includes Alzheimer’s disease (AD).
Consequently, numerous studies targeting different
components of the disease have been initiated to reduce
tau pathology as well as amyloid-b. These include inhi-
bition of kinases which phosphorylate tau, such as gly-
cogen synthase kinase-3b (GSK3b) [5-8], manipulating
heat shock proteins [9-11], immunotherapy which tar-
gets the tau peptide and subsequently reduces p-tau
levels, [12,13], and modifying p-tau by manipulating the
immune response [14]. Some reports indicate that
pathological tau induces inflammation [15] and that
inflammation modifies tau [16,17].
Inflammation arguably plays a significant role in the
progression of AD pathology. The microglial activation
state contributes to many of the ongoing debates, and it
is believed that microglia can cause both beneficial and
detrimental effects, depending on the microenvironment
and cytokines involved. Recently, more attention has
been paid to the functional status of microglia rather
than generalized activation by generic markers. As more
studies emerge identifying selective markers that repre-
sent different phenotypic activation states of microglia,
an association of their role during disease pathology is
being revealed. In the classical or M1 state, pro-inflam-
matory cytokines produce tissue damage and pathogen
destruction, whereas the alternative activation state
(M2) dampens this response and directs tissue repair
and healing responses [18]. Some reports suggest that in
chronic neurodegenerative diseases like AD, a hybrid
activation state exists including markers of both M1 and
* Correspondence: dlee1@health.usf.edu; scientist.dave@gmail.com
1Byrd Alzheimer’s Institute, Department of Molecular Pharmacology and
Physiology, University of South Florida, Tampa, Fl 33612, USA
Full list of author information is available at the end of the article
Lee et al. Journal of Neuroinflammation 2010, 7:56
http://www.jneuroinflammation.com/content/7/1/56
JOURNAL OF 
NEUROINFLAMMATION
© 2010 Lee et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.M2 phenotypes [19]. Other reports argue that beginning
stages of AD pathology in animal models of amyloid-b
deposition resemble an M2 state that switches to a
more classical response with age [20]. It is possible the
phenotypic state of microglia in response to amyloid-b
deposition influences certain aspects of tau pathology as
well. Thus, it is important to identify the components of
inflammation that promote vs. reduce tau pathology in
order to design better therapeutic strategies which target
the immune response.
In previous studies [21-25], intracranial LPS, which
induces both M1 and M2 markers, activates microglia
and reduces Ab pathology in APP transgenic models of
amyloid deposition. This requires microglial activation
and can be suppressed by dexamethasone administered
systemically. Importantly, there is no indication for sys-
temic inflammation in AD patients [26]. Herein, we
similarly provoked central microglial activation by LPS
to evaluate phospho-tau species and pathology in the
rTg4510 mice. This model develops tangle pathology in
the higher forebrain cortical layers and hippocampus
coupled with cognitive deficits and neuronal loss
[1,4,27]. To our knowledge, this is the first report show-
ing that activation of inflammation in the brain exacer-
bates tau phosphorylation.
Methods
Mouse breeding, tissue preparations, and animal
treatments
The rTg4510 mice, lines carrying the parental tau muta-
tions and the tetracycline-controlled transactivator pro-
tein (tTA) were used [3]. For age-related microglia
activation, brains were harvested from 1, 5, or 9 month
old rTg4510 mice and their non-transgenic littermates.
For lipopolysaccharide (LPS) studies, male and female
mice were aged 4.5 months and a volume of 2 μl of LPS
(5 μg/μl; Salmonella abortus equii, Sigma-Aldrich, St.
Louis MO) in was unilaterally injected into the hippo-
campus and anterior cortex (frontal cortex area3) of
rTg4510 and non-transgenic littermates. Stereotaxic
coordinates from bregma were +1.7 mm anteroposterior,
-2.2 mm lateral and -2.5 mm vertical for frontal cortex,
and, -2.7 mm anteroposterior, -2.7 mm lateral and -3.0
mm vertical for hippocampus. The solution was dis-
pensed at a constant rate of 0.5 μl/min. Seven days post
injection; mice were weighed and overdosed with 100
mg/kg of pentobarbital. Mice were then perfused intra-
cardially with 25 ml of 0.9% saline. The brain was
removed, and immersion fixed in 4% paraformaldehyde
in 100 mM PO4 buffer (pH 7.4) for 24 hours. The tissue
was cryoprotected in a series of 10%, 20% and 30%
sucrose solutions. Horizontal sections were cut at
25 μm using a sliding microtome and stored at 4°C in
Dulbecco’s phosphate buffered saline containing
100 mM sodium azide for immunohistochemistry.
Immunohistochemistry and silver stain
Immunohistochemistry was performed on free floating
sections as described in detail previously [28]. Sections
were incubated with primary antibodies rat anti-mouse
CD45 (1:3000) (Serotec, Raleigh, NC), rat anti-major
histocompatibility complex -II (1:5000) (MHCII; BD
Pharmigen), rabbit anti-mouse chitinase 3-like-3
(1:3000) (YM1; StemCell Technologies, Vancouver,
Canada), chicken anti-arginase 1 (1:50,000)(generous gift
from Dr. S.M. Morris)[29], rabbit anti-human phospho-
tau ser199/202 (1:65,000)(Anaspec, Fremont, CA), rabbit
anti-human phospho-tau ser396 (1:3000) (Anaspec,
Fremont, CA), or rabbit anti- human full length-tau
(1:3000) (H-150, sc-5587, Santa Cruz Biotechnology,
Santa Cruz, CA), AT8 (1:5000) (Thermo Scientific,
Rockford, IL overnight at 4°C, then incubated in the
appropriate biotinylated secondary antibody (Vector-
Labs, Burlingame, CA) for 2 h followed by a 1 hr incu-
bation in ABC (Vector Labs, Birlingame, CA). Color
development was performed using 0.05% 3, 3’-diamino-
benzidine (DAB; Sigma, St.L o u i s ,M O )e n h a n c e dw i t h
0.5% nickelous ammonium sulfate (J. T. Baker Chemical
Company, Phillipsburg, NJ). For silver staining, a series
of sections stained using Gallyas silver stain method [2].
Briefly, sections were fixed in 4% paraformaldehyde in
100 mM PO4 buffer (pH 7.4) for 24 hours, horizontally
sectioned at 25 μm thickness, and stored at 4°C in Dul-
becco’s phosphate buffered saline containing 100 mM
sodium azide. Free floating sections were mounted on
slides and processed together using Gallyas silver stain
method with the omission of a counter stain for quanti-
tative analysis. It should be noted for time courses and
LPS studies that all tissue sections for each immunohis-
tochemical stain and the Gallyas silver stain that was
analyzed together were processed together at the same
time under the same conditions.
Immunofluorescence
Immunohistochemistry was performed on free floating
sections as previously describe above with slight modifi-
cations to primary antibody concentrations. Sections
were incubated with primary antibodies rat anti-mouse
CD45 (1:1000), rabbit anti-human phospho-tau ser199/
202 (1:10,000), rabbit anti-mouse chitinase 3-like-3
(YM1) (1:1000), rabbit anti-human phospho-tau ser396
(1:1000), rabbit anti- human full length-tau (1:2000)
(H-150), biotinylated AT8 (1:5000) (Thermo Scientific,
R o c k f o r d ,I L )o v e r n i g h ta t4 ° C ,w a s h e da n di n c u b a t e d
with the appropriate secondary Alexa Fluor antibodies
for 2 h (Invitrogen); goat anti-rabbit Alexa 488, goat
Lee et al. Journal of Neuroinflammation 2010, 7:56
http://www.jneuroinflammation.com/content/7/1/56
Page 2 of 16anti-rat Alexa 488, Streptavidin Alexa 594, donkey anti-
chicken Alexa 488, goat anti-rabbit Alexa 594. Sections
were mounted on slides with Vectashield, (Vector Labs,
Burlingame, CA).
Image analysis quantification and statistics
Immunohistochemical staining was quantified with
Image Pro Plus (Media Cybernetics, Silver Spring, MD)
image software. Positively labeled microglia or tau posi-
tive neurons were segmented using RGB intensity. Each
brain section was imaged at 100× magnification in the
anterior cortex centered on the injection site (frontal
cortex, area 3), the CA1 or CA3 region of the hippo-
campus, and entorhinal cortex (caudomedial). Data were
obtained as a percent area of the image field that was
positively stained by immunochemical or histochemical
reaction product. Some sections were digitized on the
Zeiss Mirax slide scanner. All values (8 sections)
o b t a i n e df r o mas i n g l em o u s ew e r et h e na v e r a g e dt o
represent a single value for each brain region. Statistical
analysis was performed using 2-way ANOVA (Age and
Treatment), followed by Fisher’sL S Dp o s th o cm e a n s
comparison test with p values of <0.05 considered sig-
nificant using Stat View software version 5.0 (SAS Insti-
tute Inc, Cary NC). Graphs were generated using
GraphPad Prism 4.0 (La Jolla, CA).
Results
Age-related CD45 activation in rTg4510 mice
Previous work has characterized age-related accumula-
tion of various phospho-tau species in forebrain areas
and hippocampus of rTg4510 mice [30]. A cross-sec-
tional analysis showed accumulation of insoluble tau
species as early as 5.5 months of age. Herein, we evalu-
ated CD45, MHCII and an alternative activation marker,
YM1, as markers of microglial activation at 1, 5, and 9
months of age in rTg4510 mice and their non-trans-
genic littermates. Representative images of anterior cere-
bral cortex and hippocampus after immunostaining for
CD45 are presented in Fig. 1. Neither nontransgenic nor
rTg4510 display appreciable staining at one month of
age in either cortex (Fig. 1A, B) or hippocampus (Fig.
1H, I). More staining is apparent in sections from older
mice (Fig. 1C-F, J-K). Significant activation of CD45 was
observed at 9 months in the anterior cortex (Fig.1G)
and hippocampus (Fig.1N) compared with age-matched,
nontransgenic littermates. Furthermore, CD45 expres-
sion of 9 month old rTg4510 mice was significantly
greater than observed in either 1 or 5 month old mice
in the hippocampus (Fig. 1N) and greater than 1 month
old mice in cortex (Fig.1G).
We also examined the microglial markers MHC II and
YM-1 as a function of age in rTg4510 mice and their
nontransgenic littermates. However, although occasional
m i c r o g l i aw e r ep o s i t i v ef o rM H CI I ,t h e s ew e r eo n l y
observed in 9 month old rTg4510 mice (data not
shown). We failed to detect any positive YM1 microglia
at any age. These data show that age-related accumula-
tion of pathological tau induces CD45 activation in the
forebrain of rTg4510 mice.
LPS induced CD45, YM1 and arginase-1 in rTg4510 mice
Previous data show that certain inflammatory events
modify the pathology in animal models which deposit
amyloid [24]. LPS-induced microglial activation reduces
amyloid burdens in the brains of APP Tg2576 mice
w i t h i no n ew e e k[ 2 3 ] .W eu s e das i m i l a ra p p r o a c ht o
evaluate tau pathology 1 week following intracranial LPS
administration into anterior cortex and hippocampus.
LPS injections dramatically induced CD45 activation on
the ipsilateral side of the anterior cortex (Fig. 2A-E),
hippocampus (Fig. 2F-J), and entorhinal cortex (Fig. 2K-
O) compared to vehicle- treated mice in both rTg4510
mice and nontransgenic littermates. Furthermore, signif-
icant LPS-induced CD45 activation was also observed
on the contralateral side of the cortex and hippocampus
compared to vehicle-treated mice (Table 1), although to
a lesser extent. The magnitude of LPS-induced CD45
activation was similar in rTg4510 and non-transgenic
mice.
LPS also significantly increased the alternative activa-
tion marker YM1 in the ipsilateral hemisphere of the
anterior cortex (Fig. 3A-E), hippocampus (Fig. 3F-J), and
entorhinal cortex (Fig. 3K-O) compared to vehicle-trea-
ted groups in both rTg4510 mice and in nontransgenic
littermates. However, unlike CD45 activation, YM1
induction was significantly greater in rTg4510 mice
compared to non-transgenic mice. Furthermore, YM1
activation also increased on the contra-lateral hemi-
sphere following LPS (Table 1) and this response was
also augmented in the hippocampus and entorhinal cor-
t e xo fr T g 4 5 1 0m i c ec o m p a r e dt on o n t r a n s g e n i c
littermates.
We also evaluated arginase 1, typically associated with
alternative activation. LPS induced robust expression of
arginase 1 staining on the ipsilateral side of the anterior
cortex (Fig 4A-E), hippocampus (Fig. 4F-J), and entorh-
inal cortex (Fig. 4K-O) compared to vehicle-treated
mice. There was no difference in the size of arginase 1
induction between rTg4510 and nontransgenic mice.
LPS-Induced inflammation exacerbates phospho-tau
pathology
To evaluate the effects of LPS-induced inflammation on
tau pathology, we measured pre-tangle pathology by phos-
pho-tau staining, in addition to mature insoluble tangle
pathology by Gallyas silver stain. At 5 months, detectable
levels of tau phosphorylated at epitope ser199/202 were
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LPS significantly increased p-tau ser199/202 in the ante-
rior cortex (Fig. 5A-E) and entorhinal cortex (Fig. 5K-O)
in rTg4510 mice compared to the vehicle- treated
rTg4510 mice. Although the mean % area for staining of
phospho-tau ser199/202 in the hippocampus following
LPS administration showed an elevated trend (Fig. 5F-J), it
failed to reach statistical significance. Likewise, phospho-
tau epitope ser396 was observed in vehicle-treated mice
along axonal processes and in perinuclear regions, yet
LPS-induced inflammation further increased phospho-tau
ser396 immunoreactivity in the cortex (Fig. 6A-E), hippo-
campus (CA1; Fig. 6F-J), and entorhinal cortex (Fig. 6K-O)
compared to rTg4510 mice treated with vehicle. Neither
phospho-tau species (tau ser199/202 or ser396) was
detectable at the immunohistochemical level in nontrans-
genic mice which received vehicle or LPS administration.
To identify the impact of LPS-induced inflammation on
pre-tangle and mature tau pathology, we measured Gallyas
silver staining in rTg4510 mice and nontransgenic
Figure 1 Age-related, Tau Induced CD45 activation. Immunohistochemistry was performed for CD45 in rTg4510 and nontransgenic (nTg)
littermates aged 1 (A, B, H, I), 5 (C, D, J, K), and 9 (E, F, L, M) months in the anterior cortex (A-F) and hippocampus (H-M). Panels G and N
present mean ± S.E.M of % Area for immunostaining of CD45+ microglia in the anterior cortex and hippocampus, respectively. Statistical analysis
was performed using 2-way ANOVA followed by Fisher’s PLSD multiple comparison test. Area stained for CD45 significantly increased in rTg4510
mice at 9 months of age in the anterior cortex and hippocampus compared with nontransgenic littermates or with younger mice. Lines above
relevant bars display significant differences between groups (*p < 0.05), n = 4-5. Sections were digitized and representative images were taken at
40× magnification. Scale bar represents 50 μm.
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Page 4 of 16Figure 2 LPS-Induced CD45 Activation in rTg4510 and nontransgenic mice.T h em i c r o g l i am a r k e rC D 4 5w a se x a m i n e db y
immunohistochemical staining in anterior cortex, hippocampus (CA1), and entorhinal cortex (ECX) after LPS administration. rTg4510 mice or
nontransgenic (nTg) littermates were injected unilaterally with LPS or vehicle into the anterior cortex and hippocampus, followed by 1 week
survival. Representative images from anterior cortex of nontransgenic (A, C) or rTg4510 mice (B, D) from vehicle- (A, B) or LPS-injected (C, D)
mice are shown. Images (F-I) were collected from the CA1 stratum radiatum (CA1) of non-transgenic (F, H) or rTg4510 mice (G, I) after vehicle
(F, G) or LPS (H, I) injection. Similar images (K-N) were collected from the entorhinal cortex (ECX) of nontransgenic (K, M) or rTg4510 mice (L, N)
after vehicle (K, L) or LPS (M, N) injection. Quantitation of % area containing positive immunostaing is presented for each brain region in E, J,
and O (mean ± S.E.M, n = 6-8). CD45+ staining increased in both rTg4510 and nontransgenic littermates in anterior cortex, CA1, and ECX of
mice treated with LPS compared to vehicle-treated mice. Statistical analysis was performed using 2-way ANOVA followed by Fisher’s PLSD
multiple comparison test. The asterisk indicates *p < 0.05), n = 6 = 8. Scale bar represents 20 μm.
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age had small but measurable amounts of Gallyas silver
positive neurons. Following LPS administration no signifi-
cant increases or decreases were observed in the anterior
cortex (Fig. 7A-E), hippocampus (Fig. 7F-J), or entorhinal
cortex (Fig. 7K-O) of rTg4510 mice. This suggests that
acute LPS-induced microglial activation impacts tau phos-
phorylation but, at least within the first week, does not
affect the pre- and mature tangles as determined by Gal-
lyas stain.
We also evaluated full-length tau in the anterior cor-
tex, hippocampus, and entorhinal cortex by immunohis-
tochemistry (Fig. 8). As observed with the silver stain,
tau (H-150) antibody failed to recognize endogenous
mouse tau in nontransgenic mice, under these staining
conditions at the immunohistochemisrty level (Fig.8A-
F). However, detectable levels were observed in rTg4510
mice (Fig. 8G-H) in cortical regions and hippocampus,
but were not increased by LPS treatment (Fig. 8M) as
was the case for phospho-tau markers potentially due to
recognition of multiple isoforms.
Double labeling of phospho-tau and microglia
To further identify the relationship between phospho-
tau expressing cells and microglia, we performed double
labeling studies on rTg4510 mice following LPS injec-
tions. Arginase-1 expression was observed in rod and
amoeboid-like with some branching cells (Fig. 9A-C)
and failed to co-localized with cells stained for phospho-
tau Ser396. YM1 positive cells were highly branched
and also failed to co-localize with cells stained with the
AT8 (phospho-tau Ser202/Thr205) (Fig.9D-F), however
several YM1 positive microglia were clustered around
AT8 positive neurons. Furthermore, CD45 positive cells
displayed various cell morphologies from highly
branched to amoeboid/rod and macrophage-like. In gen-
eral, CD45 activation increased around tau laden areas
(phospho-tau Ser199/202 and total tau) such as hippo-
campus (Fig. 9G-L). Overall, there was rarely cell to cell
association and microglia failed to clearly co-localize
with phospho-tau positive neurons.
Discussion
In this study, we show that the phosphorylated tau spe-
cies previously characterized in the rTg4510 mice [30]
are associated with age-related microglial activation as
measured by CD45 Further activation of microglia by
LPS enhances tau phosphorylation. Prior work [30],
demonstrated that young mice possess the ability to
clear soluble phospho-tau species, showing reductions in
these markers between 1 and 3 months. However, by
5.5 months, insoluble tau aggregates appear in parallel
with accumulation of a 64 kD soluble tau species. Thus,
microglial activation begins at this age when soluble and
insoluble tau species are present. When microglial acti-
vation is provoked by LPS challenge at this point, there
are clear increases in the phosphorylation of tau. Pre-
vious studies showed that LPS-induced microglial activa-
tion in APP mice clears amyloid-b pathology in the CNS
as early as 3 days following intracranial injection
[21-24]. Using this same paradigm, LPS-induced micro-
glial activation in rTg4510 mice exacerbates pre-tangle
pathology as visualized by phospho-tau staining. This
highlights the need to include mouse models of tau
Table 1 LPS-Induced Microglia Activation on Contralateral Hemisphere
nTg rTg4510
CD45 Region Vehicle LPS Vehicle LPS
CX 0.008 ± 0.003 0.397 ± 0.162 0.161 ± 0.110 0.778 ± 0.270
a
CA1 0.027 ± 0.015 0.410 ± 0.100 0.250 ± 0.151 0.489 ± 0.154
a
CA3 0.061 ± 0.020 2.325 ± 0.431 0.112 ± 0.024 1.310 ± 0.527
a
ECX 0.530 ± 0.093 0.920 ± 0.182 0.541 ± 0.118 0.875 ± 0.409
YM1 Region Vehicle LPS Vehicle LPS
CX 0.001 ± 0.001 0.024 ± 0.005 0.001 ± 0.001 0.018 ± 0.006
a
CA1 0.003 ± 0.002 0.025 ± 0.007 0.002 ± 0.001 0.100 ± 0.036
a,b
CA3 0.001 ± 0.001 0.049 ± 0.008 0.004 ± 0.002 0.154 ± 0.049
a,b
ECX 0.005 ± 0.002 0.080 ± 0.020 0.001 ± 0.001 0.586 ± 0.189
a,b
Arg-1 Region Vehicle LPS Vehicle LPS
CX 0.008 ± 0.001 0.012 ± 0.005 0.005 ± 0.001 0.008 ± 0.002
CA1 0.014 ± 0.002 0.020 ± 0.007 0.008 ± 0.003 0.013 ± 0.003
CA3 0.017 ± 0.002 0.044 ± 0.024 0.007 ± 0.002 0.047 ± 0.023
ECX 0.021 ± 0.004 0.039 ± 0.014 0.016 ± 0.005 0.030 ± 0.010
For each marker, 2-way ANOVA follwed by Fisher’s LSD Analysis for genotype and treatment were performed. ap < 0.05, Vehicle v.s LPS; bp < 0.05, nTg v.s
rTg4510 mice. CD45; microglial activation marker, YM1; microglial alternative activation marker, Arginase-1; alternative activation marker. CX; anterior cortex, CA1
and CA3; hippocampus CA1 and CA3 respectfully, ECX; entorhinal cortex. n = 5-8.
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Page 6 of 16Figure 3 Exaggerated YM1 Activation in rTg4510 mice. Immunohistochemical staining for the microglial alternative activation marker YM1 in
cortex, hippocampus (CA1), and entorhinal cortex (ECX) was performed. rTg4510 mice or nontransgenic (nTg) littermates were injected with LPS
or vehicle into the anterior cortex and hippocampus. Images (A-D) were collected from the anterior cortex of nontransgenic (A, C) or rTg4510
mice (B, D) injected with either vehicle (A, B) or LPS (C, D), from stratum radiatum of CA1 of nontransgenic (F, H) or rTg4510 mice (G, I) after
vehicle (F, G) or LPS (H, I) injections, or from entorhinal cortex (ECX) of nontransgenic (K, M) or rTg4510 mice (L, N) which received vehicle (K,L)
or LPS (M, N) injections one week previously. Mean ± S.E.M (n = 6-8) of % Area for immunostaining of YM1+ microglia (black) in the anterior
cortex, CA1, and ECX are presented in E, J, and O. YM1+ staining increased in CX, CA1, and ECX of mice treated with LPS compared to vehicle-
treated mice. Inductions in rTg4510 mice were larger than in nontransgenic littermates. Statistical analysis was performed using 2-way ANOVA
followed by Fisher’s PLSD multiple comparison test (*p < 0.05), n = 6-8. Scale bar represents 20 μm.
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Page 7 of 16Figure 4 LPS-Induced Arginase 1 Activation in rTg4510 and nontransgenic mice. rTg4510 mice or non-transgenic (nTg) littermates were
injected with LPS or vehicle, and sections were stained using immunohistochemistry for the microglial marker arginase 1. Digital images from
the anterior cortex (A-D) of nontransgenic (A, C) or rTg4510 mice (B, D) injected with vehicle (A, B) or LPS (C, D), from CA1 of nontransgenic
(F, H) or rTg4510 mice (G, I) after injections of vehicle (F, G) or LPS (H, I), or entorhinal cortex (ECX) of nontransgenic (K, M) or rTg4510 mice
(L, N) after vehicle (K,L) or LPS (M,N) injections are presented. Panels E, J, and O display mean ± S.E.M (n = 6-8) of % Area for immunostaining of
arginase 1 positive microglia (black) in the anterior cortex, CA1 CX, and ECX respectively. Arginase 1 staining increased in both rTg4510 and
nontransgenic littermates in cortex, CA1, and ECX after treatment with LPS compared to vehicle- treated mice, and the magnitude of the
induction was similar in rTg4510 and nontransgenic mice. Statistical analysis was performed using 2-way ANOVA followed by Fisher’s PLSD
multiple comparison test (*p < 0.05), n = 6-8. Scale bar represents 20 μm.
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Page 8 of 16Figure 5 Increased phosphor-tau staining after LPS. Immunohistochemical staining of tau phosphorylated at Ser199/202 in anterior cortex
(A-D), hippocampus (CA1; F-I), and entorhinal cortex (ECX; K-N) after vehicle (A, B, F, G, K, L) or LPS (C, D, H, I, M, N) administration in rTg4510 (B,
D, G, I, L, N) or nontransgenic control mice (A, C, F, H, K, M). Panels E, J and O present mean ± S.E.M of % Area for immunostaining. Phospho-
Tau Ser199/202 staining increased in both anterior cortex and ECX of rTg4510 mice treated with LPS compared to vehicle- treated mice. No
staining was detected in nontransgenic littermates. Statistical analysis was performed using 2-way ANOVA followed by Fisher’s PLSD multiple
comparison test. (*p < 0.05), n = 6-8. Scale bar represents 20 μm.
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Page 9 of 16Figure 6 A second phospho-tau epitope was also increased after LPS. Immunohistochemical staining of tau phosphorylated at Ser396 in
cortex anterior cortex (A-D), hippocampus (CA1; F-I), and entorhinal cortex (ECX; K-N) after injections of either vehicle (A, C, F, H, K, M) or LPS (B,
D, G, I, L, N) in nontransgenic (A, C, F, H, K, M) or rTg4510 (B, D, G, I, L, N) mice. The % Area for immunostaining of phospho-tau Ser396 (mean ±
S.E.M; n = 6-8) is presented for each brain region in E, J, and O. Phospho-tau Ser396 staining increased in anterior cortex, CA1, and ECX of
rTg4510 mice treated with LPS compared to vehicle-treated mice. No staining was detected in nontransgenic littermates. Statistical analysis was
performed using 2-way ANOVA followed by Fisher’s PLSD multiple comparison test (*p < 0.05), n = 6-8. Scale bar represents 20 μm.
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Page 10 of 16Figure 7 Argyrophilic tau inclusions did not increase after LPS. Argyrophilic tau was identified with the Gallyas silver stain in cortex (A-D),
hippocampus (CA1; F-I), and entorhinal cortex (ECX; K-N) in nontransgenic (A, C, F, H, K, M) and rTg4510 (B, D, G, I, L, N) mice after injection with
LPS (B, D, G, I, L, N) or vehicle (A, C, F, H, K, M). Panels E, J, and O present mean ± S.E.M of % Area for Gallyas silver positive staining. There were
no significant changes in silver positive neurons in any brain region of mice treated with LPS compared to vehicle-treated mice. Statistical
analysis was performed using 2-way ANOVA followed by Fisher’s PLSD multiple comparison test (*p < 0.05), n = 6-8. Scale bar represents 20 μm.
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Page 11 of 16Figure 8 Total tau was not increased by LPS. Immunohistochemical staining using an antibody that recognizes multiple isoforms of tau
regardless of phosphorylation is presented in anterior cortex (CX; A, B, G, H), hippocampus (CA1; C, D, I, J), and entorhinal cortex (ECX; E, F, K, L)
after vehicle (A, C, E, G, I, K) or LPS (B, D, G, H, J, L) administration in nontransgenic (A-F) or rTg4510 (G-L) mice. No immunoreactive staining was
observed for total tau in nontransgenic littermates. Mean ± S.E.M (n = 6-8) of % Area for total tau positive staining (M) reveals that there were
no significant changes in tau positive staining in the CX, CA1, or ECX of mice treated with LPS compared to vehicle-treated mice. Statistical
analysis was performed using 2-way ANOVA followed by Fisher’s PLSD multiple comparison test. Scale bar represents 20 μm.
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Page 12 of 16pathology as well as models of amyloid pathology when
assessing the impact of potential treatments for transla-
tion in to clinical trials in Alzheimer cases.
Another previous study using a 3xTg-AD model (har-
boring APPK670N; M671L , PS1M146V , and Taup301L muta-
tions) showed no changes in APP processing after 6
weeks of peripheral administration of LPS. However,
phosphorylation of tau at specific sites (AT-180, p231/
235; AT8, p202/205; but not PHF-1, p396/404) was
increased within the hippocampus, in a cyclin kinase 5-
dependent mechanism [16]. Another pro-inflammatory
stimulus, interleukin-1b, also resulted in microglial acti-
vation and tau phosphorylation in cortical neurons [17].
Herein, we show that acute activation of microglia by
Figure 9 Immunofluorescent labeling of microglial activation and phospho-tau in rTg4510 mice treated with LPS. Panels A-C shows
immunofluorescent staining of arginase-1 positive microglia (green; A, C) and phospho-tau ser396 (red; B, C) in the anterior cortex. Panels D-F
shows YM1 positive microglia (green; D, F) and AT8 (phospho-tauSer202/Thr204) (red; E, F) in the anterior cortex. Panels G-L shows increased
CD45 positive microglia (Green; G, I, J, L), phospho-tauSer199/202 (red; H, I), and full-length tau (red; K, L) in the hippocampus CA region.
Activated microglia failed to co-label with phospho-tau markers. Images were taken at 20x objective. Scale bar represents 20 μm.
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Page 13 of 16LPS increased phospho-tau staining within one week,
not only in the hippocampus and anterior cortex, but
also in other tau-laden areas that were not injected
including entorhinal cortex. Although the level of
microglial activation also increased in the entorhinal
cortex to a lesser extent than that of the hippocampus
and anterior cortex, the increased phospho-tau species
observed distal to the injection site is conceivable from
previous findings of systemic inflammation and CNS
effects on phospho-tau [16] and supports the potential
role for diffusible ligands and cytokines and their impact
on tau pathology. Although these data suggest that
acute inflammatory conditions may accelerate the course
of neurodegenerative tauopathies or AD, other models
of low level chronic neuroinflammation should be
explored in a similar context [31].
With normal aging up to 9 months, CD45 positive
microglia increased in parallel with tau pathology, yet
the alternative activation marker YM1 was not detected
at the protein level by immunohistochemistry. However,
upon LPS challenge, YM1 was elevated to a significantly
greater level in rTg4510 mice with pre-existing tau than
in nontransgenic mice. Thus, not only does microglia
activation appear to influence tau pathology but tau
pathology appears to impact the phenotypic responses
of microglia as well.
It has yet to be determined whether this exaggerated
YM1 activation occurred in response to insoluble vs.
soluble tau species or even other specific tau forms such
as truncated tau. A recent report showed that human
misfolded, truncated tau protein promoted the up-regu-
lation of immune molecules in microglia/macrophages
and caused the influx of antigen-presenting cells from
blood into the CNS of transgenic rats [15]. It is also
unknown whether YM1 influences the pathological state
of tau, however recent reports show YM1 protein
expression localizes around the amyloid plaques of APP/
PS1 transgenic mice, and AD brains contain increased
YM1 mRNA compared to normal, aged -matched con-
trol brains [19,20]. This implies that amyloid pathology
can increase YM1 expression. YM1, whose function is
poorly understood, exists as a secretory protein transi-
ently expressed in microglia/macrophages during hema-
topoiesis [32], during parasitic infection or after
interleukin-4/interleukin-13 cytokine stimulation [33].
YM1 shows specific binding affinity to glucosamine,
galactosamine, and heparin sulfate, which has been
hypothesized as a mechanism for shielding or maintain-
ing macrophage integrity during parasitic infection
[32,34]. Interestingly, heparin sulfate and sulfated glyco-
saminoglycans prevent tau from binding to microtu-
bules, promote microtubule disassembly, and stimulate
tau phosphorylation by several kinases [35]. Although,
LPS induced inflammation and tau pathology seems to
influence the expression of YM1, it is unclear if up-reg-
ulation of YM1 by cytokines or amyloid-b deposition
directly impacts the tau pathology.
Gene delivery of the pro-inflammatory cytokine tumor
necrosis factor alpha (TNF-a) into the CNS of 3xTg-AD
mice resulted in accumulation of both Ab42 and phos-
pho-tau species [36]. Conversely, chronic ibuprofen
treatment in 3xTg-AD mice reduced oligomeric amy-
loid-b, hyperphosphorylated tau, and improved memory
deficits [37]. However, overexpression of the pro-inflam-
matory and M1-stimulating cytokine, interferon gamma,
using AAV resulted in differential effects on amyloid-b
and phospho-tau[14]. The authors observed increased
levels of amyloid-b but reduced levels of phospho-tau,
contradicting results with INF-g in 3xTg-AD mice [14].
Given the evidence that the amyloid deposition drives
tau pathology in this 3xTg-ADm o d e l[ 1 2 ] ,i ti su n c l e a r
whether direct effects on tau or indirect effects on amy-
loid are responsible for changes in tau pathology.
Transgene regulated over-expression of the M1-stimu-
lating cytokine, interleukin-1 in APP mice caused reduc-
tions in amyloid pathology [38]. Similarly, AAV-
mediated over-expression of interleukin-6 in TgCRND8
and Tg2576 mice elicited massive gliosis and reductions
in amyloid-b pathology [39]. The microglial phenotype
in these mice included increased YM1, but not other
M2 activation markers such as arginase 1. In our study,
we observed a tau transgene facilitation of YM1 induc-
tion following LPS in both hemispheres, but this effect
was not evident for arginase 1activation, another puta-
tive M2 activation marker. This raises questions regard-
ing how particular M2 activation state markers are
regulated by proinflammatory stimuli and why RNA and
protein levels of YM1 are increased in AD patients and
animal models of amyloid deposition, which are typically
considered to be associated with a proinflammatory
(M1) cytokine environment [19,20]. These observations
are important in considering the ultimate goals for ther-
apeutic tuning of the microglial phenotype in order to
reduce amyloid and/or tau pathology. Some dichoto-
mous effects in the different transgenic models and
therapeutic treatments make interpretations and poten-
tial translation to AD challenging. These results suggest
a more complex set of microglia phenotypes than the
dipolar M1/M2 characterization, and suggest that the
clearance of amyloid pathology and tau pathology may
be mediated by distinct activation subtypes.
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